Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-90What’s the place of immunotherapy in malignant mesothelioma treatments?
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-42[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia]
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2007-02-01 / Cir Esp 2007 Feb;81(2):82-6[Immunotherapy and malignant mesothelioma: clinical perspectives]
/in International Publications, Malignant Pleural Mesothelioma /von 2007-01-01 / Bull Cancer 2007 Jan;94(1):23-31Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2006-11-01 / Int J Hyperthermia 2006 Nov;22(7):613-21Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
/in International Publications, Malignant Pleural Mesothelioma /von 2006-03-15 / Eur. Respir. J. 2006 Jun;27(6):1086-95Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-30
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de